Medication Fact Book for Psychiatric Practice, Fifth Edition

Medication Fact Book

For Psychiatric Practice

Fifth Edition

Published by Carlat Publishing, LLC

PO Box 626, Newburyport, MA 01950

Publisher and Editor-in-Chief: Daniel J. Carlat, MD

Deputy Editor: Talia Puzantian, PharmD, BCPP

Executive Editor: Janice Jutras

All rights reserved. This book is protected by copyright.

This CME/CE activity is intended for psychiatrists, psychiatric nurses, psychologists, and other health care professionals with an interest in mental health. The Carlat CME Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Carlat CME Institute is approved by the American Psychological Association to sponsor continuing education for psychologists. Carlat CME Institute maintains responsibility for this program and its content. Carlat CME Institute designates this enduring material educational activity for a maximum of twelve (12) AMA PRA Category 1 Credits™ or 12 CE credits for psychologists. Physicians or psychologists should claim credit commensurate only with the extent of their participation in the activity. The American Board of Psychiatry and Neurology has reviewed the Medication Fact Book for Psychiatric Practice and has approved this program as part of a comprehensive Self-Assessment and CME Program, which is mandated by ABMS as a necessary component of maintenance of certification. CME tests must be taken online at www.thecarlatreport.com or http://thecarlatcmeinstitute.com/self-assessment (for ABPN SA course subscribers).

To order, visit www.thecarlatreport.com

or call (866) 348-9279

1 2 3 4 5 6 7 8 9 10

ISBN #: 978-1-7329522-3-2

PRINTED IN THE UNITED STATES OF AMERICA

Table of Contents

Introduction

ADHD Medications

General Prescribing Tips

Amphetamine (Adzenys XR-ODT, Dyanavel XR, Evekeo)

Atomoxetine (Strattera)

Clonidine (Catapres, Kapvay)

Dexmethylphenidate (Focalin, Focalin XR)

Dextroamphetamine (Dexedrine)

Guanfacine (Intuniv, Tenex)

Lisdexamfetamine (Vyvanse)

Methamphetamine (Desoxyn)

Methylphenidate IR (Methylin, Ritalin)

Methylphenidate ER (Concerta, Ritalin SR and LA, others)

Methylphenidate Transdermal (Daytrana)

Mixed Amphetamine Salts (Adderall, Adderall XR)

Antidepressants

General Prescribing Tips

Brexanolone (Zulresso)

Bupropion (Wellbutrin, others)

Clomipramine (Anafranil)

Desvenlafaxine (Khedezla, Pristiq)

Duloxetine (Cymbalta)

Esketamine (Spravato)

Ketamine (Ketalar)

Levomilnacipran (Fetzima)

Mirtazapine (Remeron)

Monoamine Oxidase Inhibitors (MAOIs)

Nefazodone (Serzone)

Selective Serotonin Reuptake Inhibitors (SSRIs)

Selegiline Transdermal (Emsam)

Thyroid (Cytomel, Synthroid, others)

Trazodone (Desyrel)

Tricyclic Antidepressants (TCAs)

Venlafaxine (Effexor, Effexor XR)

Vilazodone (Viibryd)

Vortioxetine (Trintellix)

Antipsychotics

General Prescribing Tips

Aripiprazole (Abilify)

Asenapine (Saphris, Secuado)

Brexpiprazole (Rexulti)

Cariprazine (Vraylar)

Chlorpromazine (Thorazine)

Clozapine (Clozaril, FazaClo, Versacloz)

Fluphenazine (Prolixin)

Haloperidol (Haldol)

Iloperidone (Fanapt)

Loxapine (Adasuve, Loxitane)

Lurasidone (Latuda)

Molindone (Moban)

Olanzapine (Symbyax, Zyprexa)

Paliperidone (Invega)

Perphenazine (Trilafon)

Pimavanserin (Nuplazid)

Quetiapine (Seroquel, Seroquel XR)

Risperidone (Risperdal)

Thioridazine (Mellaril)

Thiothixene (Navane)

Trifluoperazine (Stelazine)

Ziprasidone (Geodon)

Long-Acting Injectable (LAI) Antipsychotics

Anxiolytic Medications

General Prescribing Tips

Alprazolam (Niravam, Xanax)

Buspirone (BuSpar)

Clonazepam (Klonopin)

Diazepam (Valium)

Lorazepam (Ativan)

Prazosin (Minipress)

Propranolol (Inderal)

Dementia Medications

General Prescribing Tips

Donepezil (Aricept)

Galantamine (Razadyne, Razadyne ER)

Memantine (Namenda, Namenda XR)

Memantine ER/Donepezil (Namzaric)

Rivastigmine (Exelon, Exelon Patch)

Hypnotics

General Prescribing Tips

Antihistamines (Diphenhydramine, Doxylamine)

Doxepin (Silenor)

Eszopiclone (Lunesta)

Flurazepam (Dalmane)

Ramelteon (Rozerem)

Suvorexant (Belsomra)

Temazepam (Restoril)

Triazolam (Halcion)

Zaleplon (Sonata)

Zolpidem (Ambien, Edluar, Intermezzo, Zolpimist)

Mood Stabilizers and Novel Anticonvulsants

General Prescribing Tips

Carbamazepine (Epitol, Equetro, Tegretol, others)

Gabapentin (Gralise, Horizant, Neurontin)

Lamotrigine (Lamictal, Lamictal XR)

Lithium (Eskalith, Lithobid)

Oxcarbazepine (Oxtellar XR, Trileptal)

Pregabalin (Lyrica)

Topiramate (Qudexy XR, Topamax, Trokendi XR)

Valproic Acid (Depakene, Depakote)

Natural Treatments

General Prescribing Tips

L-Methylfolate (Deplin)

L-Tryptophan

Melatonin

N-Acetylcysteine (NAC)

Omega-3 Fatty Acids (Fish Oil)

S-Adenosyl-L-Methionine (SAMe)

St. John’s Wort

Vitamin D

Sexual Dysfunction Medications

General Prescribing Tips

Avanafil (Stendra)

Bremelanotide (Vyleesi)

Cyproheptadine (Periactin)

Flibanserin (Addyi)

Sildenafil (Viagra)

Tadalafil (Cialis)

Testosterone (various)

Vardenafil (Levitra)

Side Effect Management

General Management Tips

Side Effect Medications

Amantadine (Gocovri, Symmetrel)

Benztropine (Cogentin)

Deutetrabenazine (Austedo)

Metformin (Glucophage, Riomet)

Trihexyphenidyl (Artane)

Valbenazine (Ingrezza)

Side Effect Symptoms

Akathisia

Bruxism

Constipation

Dry Mouth (Xerostomia)

Dystonia

Excessive Sweating (Hyperhidrosis)

Fatigue

Nausea

Orthostatic Hypotension (Postural Hypotension)

Parkinsonism

Prolactinemia

QT Interval Prolongation

Sexual Dysfunction

Sialorrhea (Hypersalivation)

Tardive Dyskinesia

Tremor

Weight Gain

Sleep Disorder Medications

General Prescribing Tips

Armodafinil (Nuvigil)

Dopamine Agonists (Mirapex, Neupro, Requip, Sinemet)

Modafinil (Provigil)

Pitolisant (Wakix)

Sodium Oxybate (Xyrem)

Solriamfetol (Sunosi)

Tasimelteon (Hetlioz)

Somatic Treatments

Bright Light Therapy

Electroconvulsive Therapy (ECT)

Transcranial Magnetic Stimulation (TMS)

Vagus Nerve Stimulation (VNS)

Substance Abuse/Dependence Medications

General Prescribing Tips

Smoking Cessation

Acamprosate (Campral)

Buprenorphine (Buprenex, Probuphine, Sublocade)

Buprenorphine/Naloxone (Bunavail, Cassipa, Suboxone, Zubsolv)

Bupropion SR (Zyban)

Disulfiram (Antabuse)

Lofexidine (Lucemyra)

Methadone (Methadose)

Naloxone (Evzio, Narcan Nasal Spray)

Naltrexone (ReVia, Vivitrol)

Nicotine Gum/Lozenge (Nicorette, others)

Nicotine Inhaled (Nicotrol Inhaler)

Nicotine Nasal Spray (Nicotrol NS)

Nicotine Patch (Nicoderm CQ, others)

Varenicline (Chantix)

Appendices

Appendix A: Drug Interactions in Psychiatry

Appendix B: Psychiatric Medications in Pregnancy and Lactation

Appendix C: Schedules of Controlled Substances

Appendix D: Lab Monitoring for Psychiatric Medications

Appendix E: Urine Toxicology Screening

Appendix F: Pharmacogenetic Testing

Appendix G: Anticholinergic Agents Often Used in Psychiatry

Introduction

How to Use This Book

Medication information is presented in three ways in this book.

Fact sheets: In-depth information for select medications, somatic treatments, and side effects. There are 148 fact sheets in this book. The medication fact sheets don’t cover all psychiatric medications, but we have included most of the commonly prescribed and newer medications.

Quick-scan medication tables: These are most often located at the beginning of each therapeutic category and list the very basics: generic and brand names, strengths available, starting doses, and target doses. These tables contain most of the commonly prescribed psychiatric medications.

Treatment algorithms: These are quick-reference decision trees to serve as a memory aid and to help in clinical decision making. They don’t cover every medical nuance but serve as general overviews.

Changes and Additions to the fIFTH Edition

Medication fact sheets have been updated to reflect availability of newer strengths and formulations, as well as generics. New clinical data have been incorporated into the previous edition’s fact sheets. Many categories of medications have been expanded to include a larger number of medications: 17 new fact sheets and 7 appendices with 6 new tables are included in this edition. Also, in this edition we’ve introduced algorithms within many of the chapters. These added flowcharts offer guidelines for treating conditions such as adult ADHD, depression, psychosis, anxiety, dementia, insomnia, bipolar mania, alcohol use disorder, and opioid use disorder. We’ve also added sections on medications for treating restless legs and using somatic therapies like bright light therapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS).

Categories of Medications

We did our best to categorize medications rationally. However, in some cases a medication can fall into more than one category. In such cases, we categorized the medication with the types of disorders for which it is most often used. If you’re having trouble finding a medication in a particular chapter, look in the index to find its page number.

More on the Medication Fact Sheets

The goal of these fact sheets is to provide need-to-know information that can be easily and quickly absorbed during a busy day of seeing patients. Our main criterion is that all the information should fit on a single page. Please refer to the PDR (Physicians’ Desk Reference) when you need more in-depth information.

For the most part, each fact sheet contains the following information:

Both the brand and generic names.

A [G] or (G) denotes generic availability.

FDA-approved indications.

Off-label uses. We list the more common off-label uses, based on both the medical literature and our own clinical experience. Just because we list a potential use does not imply that we endorse a medication as being particularly effective for that use. We are simply alerting you to the fact that there is some evidence for efficacy.

Dosage forms, along with available strengths.

Dosage guidance. We provide recommendations on how to dose medications; these are derived from a variety of sources, including package inserts, clinical trials, and common clinical practice. In other words, don’t be surprised when our dosing instructions are at odds with what you find in the PDR.

Lab monitoring recommendations. We include the usual routine monitoring measures for each medication. Of course, you may need to think beyond the routine if the clinical picture warrants it.

Cost information. Pricing information for a 1-month supply of a common dosing regimen was obtained from the website GoodRx (www.goodrx.com), accessed in July 2019. These are the prices a patient would have to pay if he or she had no insurance (GoodRx also offers coupons to purchase certain medications at reduced prices). Because of wide variations in price depending on the pharmacy, we list price categories rather than the price in dollars. The categories are:

$: Inexpensive: <$50/month

$$: Moderately expensive: $50–$100/month

$$$: Expensive: $100–$200/month

$$$$: Very expensive: $200–$500/month

$$$$$: Extremely expensive: >$500/month

This begs the question, what should you do with knowledge of retail pricing? After all, most patients have some type of insurance and are therefore not going to pay retail price, but rather a co-pay. Since there’s no clear source for accurately predicting a co-pay, you can use the retail price as a clue. Meds that are very inexpensive will likely require no co-pay, while the most expensive drugs will either require a very expensive co-pay, or, more likely, will not be covered at all without an onerous pre-authorization process.

Side effects information. We break down side effects into most common vs rare but serious side effects. We generally define most common side effects as those occurring in at least 5% of patients in clinical trials, and which were at least double the rate of the placebo group. Such information is usually found in tables in the drugs’ package inserts. We also used post-marketing clinical experience as a guide in determining which side effects were common enough to make the list.

Mechanism of action. While the mechanism of action is not well established for most psychiatric drugs, we thought it would be important to report the mechanisms most commonly cited.

Pharmacokinetics, with a focus on drug metabolism and/or half-life.

Drug interactions.

Clinical pearls, which typically comment on advantages or disadvantages of a medication in comparison to others in its therapeutic category, tips for dosing or avoiding side effects, types of patients who seem to benefit the most, and so forth.

Fun facts.

Lastly, our bottom-line summary or assessment for that particular medication, which we’ve moved to the top of the page in this edition for ease of use.

Pregnancy and Lactation Risk Information

The risks and benefits of using psychiatric medications in pregnancy and breastfeeding are not as simple or clear as the previously used ABCDX categories might suggest. The newer Pregnancy and Lactation Labeling Rule (PLLR) has been implemented by the FDA, resulting in a more detailed narrative describing available risk data instead of the letter category designation. Rather than putting this information in the fact sheets, we have a separate section in Appendix B.

Other Useful Information in the Appendices

Drug interactions in psychiatry. While we do provide some information on drug interactions in the fact sheets, we also have a more extensive discussion of the topic, as well as tables of interactions for commonly prescribed drugs, the top culprits of clinically significant drug interactions in psychiatry, and MAOI-diet considerations, all in Appendix A.

Schedules of controlled substances. Just in case you can’t remember which drugs are in which DEA schedule or what each schedule means, we have you covered with a handy table in Appendix C.

Lab monitoring for psychiatric medications. We’ve included a short easy reference table listing the medications that require laboratory monitoring, along with the labs you should consider ordering, in Appendix D.

Urine toxicology screening. As substance use treatment becomes an ever more important aspect of psychiatric practice, we have added tables explaining common urine drug test detection periods, as well as false positives, in Appendix E.

Pharmacogenetic testing. Although we’re not big fans of routine pharmacogenetic testing, we’ve added a brief section providing some basic information in Appendix F.

Financial Disclosures

Dr. Puzantian and Dr. Carlat have disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to the information provided in this book.

Disclaimer

The medication information in this book was formulated with a reasonable standard of care and in conformity with current professional standards in the field of psychiatry. Medication prescribing decisions are complex, and you should use these fact sheets as only one of many possible sources of medication information. This information is not a substitute for informed medical care. This book is intended for use by licensed professionals only.

If you have any comments or corrections, please let us know by writing to us at info@thecarlatreport.com or

The Carlat Psychiatry Report, P.O. Box 626, Newburyport, MA 01950.

ADHD Medications

General Prescribing Tips

Generally, when you have a patient with ADHD symptoms, your first choice is going to be one of the psychostimulants, because these are usually more effective than the alternatives—atomoxetine, bupropion, clonidine, and guanfacine. Which psychostimulant will you choose? Here are some of the factors that will influence your decision:

Long-acting vs short-acting. Choosing between long- and short-acting stimulants is more art than science. Trial and error, combined with patient preference, will dictate the final regimen. Adults will often start with a long-acting agent so they can take a single dose in the morning and have it carry through their workday. Kids may do better with short-acting stimulants so that they will have an appetite when the medication wears off at lunch.

Amphetamine (AMP) vs methylphenidate (MPH). New data recently suggested that, based on safety and efficacy, methylphenidate is a better choice in kids and adolescents whereas amphetamine-class agents are better in adults. Generally, this is a Coke vs Pepsi decision—some people like one better than the other, and you can’t predict their preference ahead of time. We recommend a methylphenidate over an amphetamine in most cases, because amphetamines may tend to have more side effects and are more likely to be abused or diverted.

Stimulants vs non-stimulants. Stimulants are more effective than non-stimulants, so they are your first-line choice for most patients. If you have a substance abuser, start with atomoxetine. Some special clinical circumstances seem to naturally call for other options. For example, bupropion is helpful for ADHD symptoms, as well as for depression, tobacco use, and being overweight, so it might be a great choice for patients with a combination of these problems. Alpha agonists, such as guanfacine and clonidine, are helpful for both ADHD and insomnia, another potential two-fer, though these meds tend to be used more frequently for children.

Fancy formulations. There have been many new formulations of both amphetamine and methylphenidate introduced recently, and while they may have been marketed to increase drug company profits, some of them may be of clinical utility. Examples include Quillichew ER (a chewable long-acting MPH), Cotempla XR-ODT (an ODT long-acting MPH), Adzenys XR-ODT (an ODT long-acting AMP), Dyanavel XR (a long-acting liquid AMP), and most intriguingly, Jornay PM (a long-acting MPH you take at night that kicks in the next morning). We cover these formulations in the ADHD Medications table.

Cost. Most ADHD meds are available generically, but some reasonable choices are still branded and therefore more expensive. The most popular of these is Vyvanse, which is a long-acting amphetamine. Vyvanse appears to have a genuine advantage over many other stimulants, mainly in terms of tolerability and less potential for abuse. However, you’ll have a hard time convincing insurance companies to cover the cost of Vyvanse unless you can clearly document intolerance to several other trials of stimulants.

Dose Equivalents and Switching Strategies

Most patients need to try different stimulants, or stimulant formulations, before settling on the one that works best for them. The dose equivalents are, luckily, fairly easy to remember.

From amphetamine to another amphetamine

With the exception of Vyvanse, all amphetamines, including both Adderall IR and XR, are roughly equivalent in potency. For example, if a patient is taking Dexedrine 10 mg TID, you can switch this to Adderall 15 BID or Adderall XR 30 mg QD. That said, some people believe that Dexedrine, being 100% dextroamphetamine, might be more potent than Adderall, which is 75% d-amphetamine and 25% l-amphetamine (eg, Dexedrine 30 mg/day may be closer to 40 mg/day of Adderall). In reality, the effect is likely negligible in most people.

Vyvanse is composed of both lysine and amphetamine, with amphetamine making up only about 30% of Vyvanse. This means that it’s much less potent than straight Dexedrine. So, when switching from another amphetamine to Vyvanse, you have to at least double the dose.

From methylphenidate to another methylphenidate

With the exception of Concerta and Focalin, all methylphenidate preparations are roughly equivalent in potency.

Concerta, because of its complex delivery system, delivers less methylphenidate than implied by the mg amount you prescribe. The usual conversion percentage used is 83%, meaning that the body sees 83% of Concerta in methylphenidate equivalents. Thus, Concerta 18 mg is equivalent to methylphenidate 15 mg, 36 mg is equivalent to 30 mg, and so on.

Focalin is the dextro-isomer of methylphenidate, which is twice as potent as methylphenidate. Thus, use about half the dose when prescribing Focalin.

From methylphenidate to an amphetamine (or vice versa)

Methylphenidate is roughly half as potent as amphetamine, so Ritalin 10 mg = Dexedrine 5 mg, etc. Consistent with this equivalency, child psychiatrists often dose methylphenidate at 1 mg/kg, whereas they dose amphetamine at 0.5 mg/kg. Conversely, if you’re switching from Dexedrine to Ritalin, you would need to increase the dose by a factor of two.

From oral methylphenidate to the methylphenidate patch (Daytrana)

According to a clinical trial of patients switched from various versions of long-acting methylphenidate to the patch, you should dose the patch at about half the dose of the oral medication (Arnold LE et al, Curr Med Res Opin 2010;26(1):129–137).

How to Switch

Once you’ve determined the dose equivalence, the actual switching is easy. You don’t have to cross-taper; instead, have your patient take the last dose of stimulant A on day 1 and start stimulant B on day 2. To be prudent, start the new stimulant at a somewhat lower dose than you calculate would be needed based on the equivalent dose rules of thumb. Those equivalencies are based on averages and may not apply to a given individual.

Side Effects and Class Warnings

The following apply to all stimulants:

Potential to cause psychosis or aggression: This is a rare and dose-related effect; it may be more likely in patients with a predisposition for psychosis.

Worsening or new-onset Tourette’s or tic disorders: Stimulants may unmask tics. Of stimulants, methylphenidate is favored. The non-stimulant guanfacine is an even better alternative.

Seizures: Stimulants may lower the seizure threshold, although data are contradictory; monitor patients with seizure disorders closely.

Growth inhibition or weight loss: With long-term use, some growth inhibition may occur occasionally in children, but this is generally not a major problem. Monitoring growth and considering drug holidays may limit growth suppression.

Cardiovascular safety: The FDA issued a serious class warning in 2006 with regard to cardiovascular safety. However, newer data, both in children and adults, have been reassuring. Cardiac events occurred at virtually the same or lower rates among people who took stimulants compared to those who did not. From a practical perspective, we recommend asking about cardiac problems and consulting the child’s pediatrician or cardiologist if a problem exists. Amphetamines should be avoided in patients with known or suspected cardiovascular disease.

All stimulants are controlled substances, Schedule II, which means they can’t be refilled or called in. Patients must be given a new prescription every month. In most states, you are allowed to give patients post-dated prescriptions for convenience.Treatment Algorithm: Adult ADHD

Amphetamine (Adzenys XR-ODT, Dyanavel XR, Evekeo) Fact Sheet [G]

Bottom Line:

Newer formulations of an old drug come with a high price tag. Stick to the usual amphetamine products like mixed amphetamine salts unless liquid or ODT dosing is absolutely necessary.

FDA Indications:

ADHD (Adzenys XR-ODT: adults and children ≥6; Dyanavel XR: children ≥6; Evekeo: children ≥3); narcolepsy (Evekeo); obesity (Evekeo).

Off-Label Uses:

Treatment-resistant depression.

Dosage Forms:

Tablets (Evekeo, [G]): 5 mg, 10 mg (scored).

ER orally disintegrating tablets (Adzenys XR-ODT): 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg.

ER oral suspension (Dyanavel XR): 2.5 mg/mL.

Dosage Guidance:

Tablets (Evekeo, [G]):

Children 3–5: Start 2.5 mg QAM, increase in 2.5 mg/day increments weekly.

Children 6–17: Start 5 mg QAM, increase in 5 mg/day increments weekly to maximum of 40 mg/day in divided doses.

Narcolepsy: Start 5 mg QAM (ages 6–12) or 10 mg QAM (ages >12), increase by 5 mg/day or 10 mg/day increments weekly, respectively. Maximum 60 mg/day in divided doses.

ER ODT (Adzenys XR-ODT):

Start 6.3 mg QAM, increase in 3.1 mg–6.3 mg/day increments weekly. Maximum of 18.8 mg/day (ages 6–12) or 12.5 mg/day (ages 13–17 and adults).

ER oral suspension (Dyanavel XR):

Children 6–12: Start 2.5 mg–5 mg QAM, increase in 2.5 mg–10 mg/day increments every 4–7 days. Maximum 20 mg/day.

Monitoring: ECG if history of cardiac disease.

Cost: [G]: $$$; others: $$$$

Side Effects:

Most common: Abdominal pain, decreased appetite, weight loss, insomnia, headache, nervousness.

Serious but rare: See class warnings in chapter introduction.

Mechanism, Pharmacokinetics, and Drug Interactions:

Stimulant that inhibits reuptake of dopamine and norepinephrine.

Metabolized primarily via CYP2D6; t ½: 11 hours.

Avoid use with MAOIs, antacids.

Clinical Pearls:

These racemic forms of amphetamine differ from dextroamphetamine in that the l-isomer component is more potent than the d-isomer in peripheral activity (potentially resulting in more cardiovascular effects, tics).

There may be less appetite suppressant effects with a racemic